Search Results for "eric"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for eric. Results 51 to 60 of 317 total matches.
In Brief: Atorvastatin for Stroke Prevention
The Medical Letter on Drugs and Therapeutics • Sep 11, 2006 (Issue 1243)
EDITORIAL FELLOWS:
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein ...
Statins have been shown to reduce the risk of stroke in patients at high risk for cardiovascular disease (Treat Guidel Med Lett 2005; 3:15). A recent issue of The New England Journal of Medicine includes the results of a study sponsored by the manufacturer in which 80 mg of atorvastatin (Lipitor – Pfizer) or placebo was given to 4731 patients without coronary artery disease who had had a stroke or transient ischemic attack (TIA) within one to six months before study entry (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels [SPARCL] Investigators. High-dose atorvastatin after...
In Brief: Tegaserod (Zelnorm) Withdrawn
The Medical Letter on Drugs and Therapeutics • May 07, 2007 (Issue 1260)
., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein College of Medicine
DRUG ...
Tegaserod maleate (Zelnorm – Novartis), a partial serotonin 5-HT4 receptor agonist that increases gastrointestinal motility, was approved by the FDA in 2002 for short-term treatment of constipation-predominant irritable bowel syndrome in women,1 and in 2004 for treatment of chronic constipation in adults ≤65 years old. Its efficacy has not been impressive statistically, but according to Medical Letter consultants some patients with slow-transit constipation have benefited from taking the drug. Diarrhea has been its main adverse effect.2The FDA now has requested that the manufacturer stop...
In Brief: Sevelamer-Based Phosphate Binders
The Medical Letter on Drugs and Therapeutics • Feb 25, 2008 (Issue 1280)
.
CONTRIBUTING EDITOR: Eric J. Epstein, M.D. Albert Einstein College of
Medicine
CONTRIBUTING EDITOR, DRUG ...
Sevelamer carbonate (Renvela – Genzyme), a buffered form of the anion-exchange resin sevelamer hydrochloride (Renagel – Genzyme),1 has been approved by the FDA for use in patients with chronic kidney disease on dialysis. According to the manufacturer, Renvela will replace Renagel, which has been shown to induce or exacerbate metabolic acidosis in patients on dialysis. Two randomized, crossover studies found the two sevelamer salts equivalent in their ability to lower serum phosphate.2,3 Patients taking the carbonate had higher serum bicarbonate concentrations and fewer gastrointestinal...
In Brief: IV Artesunate for Severe Malaria
The Medical Letter on Drugs and Therapeutics • May 19, 2008 (Issue 1286)
.
ASSISTANT EDITOR, DRUG INFORMATION: Susan Morey, Pharm.D.
CONTRIBUTING EDITOR: Eric J. Epstein, M.D ...
The drug of choice for patients who require parenteral treatment for malaria is IV artesunate, which is available now from the CDC Malaria Branch (M-F, 8 AM-4:30 PM eastern time, 770-488-7788 or, after hours, 770-488-7100). Artesunate appears to be more effective than quinine1 and safer than quinidine, the other parenteral alternatives in the US. The CDC has supplies of artesunate in Atlanta and in 8 quarantine stations in major airports around the US. It will release the drug for appropriate patients (severe disease or unable to take oral drugs) if it can be supplied as quickly as quinidine,...
In Brief: Intensive Glucose Lowering in Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jun 30, 2008 (Issue 1289)
INFORMATION: Susan Morey, Pharm.D.
CONTRIBUTING EDITOR: Eric J. Epstein, M.D., Albert Einstein College ...
The goal for drug therapy of type 2 diabetes is achieving and maintaining a near-normal glycated hemoglobin (HbA1C) concentration without inducing hypoglycemia; the target has generally been an HbA1C of 6.5-7.0% or lower. Whether treating to this level prevents macrovascular (cardiovascular) events has been unclear. Now, 2 large randomized, double-blind trials in patients with long-standing diabetes and at high risk for cardiovascular disease have found no decrease in macrovascular events with intensive glucose control.The ACCORD trial in about 10,000 patients found that patients intensively...
In Brief: Propylthiouracil for Hyperthyroidism
The Medical Letter on Drugs and Therapeutics • Jul 27, 2009 (Issue 1317)
., University of Michigan Medical School
Eric J. Epstein, M.D. Albert Einstein College of Medicine
David N ...
The thionamides propylthiouracil and methimazole are both used to treat hyperthyroidism.1 Propylthiouracil causes severe hepatic toxicity or hepatic failure in about 0.1% of adults and children.2,3 It is the third leading cause of liver transplants due to drug toxicity (acetaminophen and isoniazid are the first two). Methimazole may cause less serious hepatic toxicity; reversible cholestatic jaundice has been reported. There is generally no good reason to continue to use propylthiouracil, with 2 possible exceptions. First, propylthiouracil may be preferred for treatment of life-threatening...
Addendum: Why Not Ertapenem for Surgical Prophylaxis?
The Medical Letter on Drugs and Therapeutics • Sep 07, 2009 (Issue 1320)
., University of Michigan Medical School
Eric J. Epstein, M.D. Albert Einstein College of Medicine
David N ...
Some readers have asked why the June 2009 issue of Treatment Guidelines (Antimicrobial Prophylaxis for Surgery) did not recommend use of ertapenem (Invanz) for prevention of infection after elective colorectal surgery. Ertapenem is a broad-spectrum carbapenem that has been approved for such use by the FDA. Medical Letter consultants do not recommend use of broad-spectrum drugs such as ertapenem, third-generation cephalosporins such as cefotaxime (Claforan), ceftriaxone (Rocephin), cefoperazone (Cefobid), ceftazidime (Fortaz, and others) or ceftizoxime (Cefizox), or fourth-generation...
Addendum: Cost of Ustekinumab (Stelara)
The Medical Letter on Drugs and Therapeutics • Mar 08, 2010 (Issue 1333)
., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein College of Medicine
David N ...
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7), footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.
In Brief: A New Hib Booster
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009 (Issue 1324)
. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D. Albert Einstein ...
In 2007, Merck voluntarily recalled some lots of PedvaxHIB and Comvax, two Haemophilus influenzae type b (Hib) vaccines, and temporarily stopped their production because of possible contamination, resulting in a shortage during which pediatricians were urged to defer giving Hib booster doses (normally given at 12-15 months) to healthy children. Now the FDA has granted accelerated licensure of Hiberix (GlaxoSmithKline), a monovalent vaccine conjugated with tetanus toxoid that has been used in Europe since 1996, as a booster (final) dose of the Hib series in children 15 months-4 years old....
Correction: Ferumoxytol (Feraheme)
The Medical Letter on Drugs and Therapeutics • Apr 19, 2010 (Issue 1336)
., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein College of Medicine
David N ...
In the Medical Letter article on Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation (2010; 52:23), the last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1 gram of sodium ferric gluconate (Ferrlecit) as about $600.